Ontology highlight
ABSTRACT:
SUBMITTER: Wang A
PROVIDER: S-EPMC5342513 | biostudies-literature | 2016 Oct
REPOSITORIES: biostudies-literature
Wang Aoli A Yan Xiao-E XE Wu Hong H Wang Wenchao W Hu Chen C Chen Cheng C Zhao Zheng Z Zhao Peng P Li Xixiang X Wang Li L Wang Beilei B Ye Zi Z Wang Jinhua J Wang Chu C Zhang Wei W Gray Nathanael S NS Weisberg Ellen L EL Chen Liang L Liu Jing J Yun Cai-Hong CH Liu Qingsong Q
Oncotarget 20161001 43
Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to be potent against EGFR mutant kinase and currently being evaluated in clinic for Non Small Cell Lung Cancer (NSCLC). Through EGFR wt/mutant engineered isogenic BaF3 cell lines we confirmed the irreversible binding mode of Ibrutinib with EGFR wt/mutant kinase via Cys797. However, comparing to typical irreversible EGFR inhibitor, such as ...[more]